- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02949414
A Study to Assess the Safety, Tolerability and Potential Efficacy of a Tracheal Replacement Consisting of a Tissue-engineered Tracheal Scaffold With Seeded Mesenchymal Cells
A Phase I Open-label Study to Assess the Safety, Tolerability and Potential Efficacy of a Novel Tracheal Replacement Consisting of a Tissue-engineered Decellularised Tracheal Scaffold With Seeded Autologous Mesenchymal Cells in Subjects With Severe Tracheal Stenosis or Malacia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a phase I study to evaluate the safety, tolerability and potential efficacy of a novel tracheal replacement therapy using a cadaveric tracheal scaffold and patients own mesenchymal cells isolated from a sample of the patients own bone marrow. The study is aimed at treating patients who suffer from severe tracheal stenosis or malacia and for whom conventional therapies are no longer adequate. A total of 4 patients will be treated during the course of this study.
A hospital multi disciplinary team will review the medical history and available treatment options for all potential patients and recommend whether they are suitable for the study. Once patients are approved they will enter an 8 week screening period. During this period bone marrow from the patient will be harvested and the manufacturing of the final graft tissue will start. The manufacturing facility will use a cadaveric donated decellularised tracheal scaffold (supplied by the NHS blood and transplant body) and the patients own cells to make the final investigational product (graft).
The product will be surgically grafted into the patient in place of the damaged tracheal section. The graft will be supported by a stent for the first 6 months with replacements of this stent occurring at week 8 and week 16 post-surgical procedure. Hospitalization for a number of days will be required during this replacement steps. The patient will be followed frequently post surgery to capture any safety and efficacy measures. Long term follow up will continue up to 5 years post surgery.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, WC1X 8DA
- Royal Nose Throat and Ear Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female subjects 18 years or older (all subjects must provide written informed consent)
- Stent or tracheostomy dependent diagnosis of tracheal stenosis or tracheomalacia (Cotton-Myers grade 2 or more)
- Subjects in the above categories for whom further conventional therapies are no longer adequate
Exclusion Criteria:
- Pregnancy
- Subjects unable to provide informed consent
- Prior tracheal transplant
- No viable bone marrow cells within the screening period
- Subjects who have conventional treatment options still available that may have additive impact
- Subject diagnosed or treated for a malignancy within 1 year of study entry or who have previously been diagnosed with a malignancy and have any radiographic or biochemical biomarker evidence of malignancy. Subjects with completely resected basal cell carcinoma or squamous cell carcinoma of the skin or in situ malignancy are not excluded
- Subject with active inflammatory or infectious conditions such as polychondritis, granulomatosis with polyangiitis ('Wegener's'), sarcoidosis or tuberculosis
- Co-morbid moderate or severe chronic obstructive pulmonary disease (COPD) as defined in Global Initiative for COPD, 2011 2, that is unrelated to tracheal stenosis or malacia
- Subjects with known presence of human immunodeficiency virus (HIV) antibody, Hepatitis B surface antigen (HbsAG) or Hepatitis C antibody
- Subject with clinically relevant or recent (within 2 years) history of substance abuse, including alcohol
- Serious medical or psychiatric illness likely to interfere with participation in the study
- Participation in any other clinical trial within previous 30 days of the start of this study or concurrent participation in another clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tracheal Replacement
Each patient will receive surgery to implant the cadaveric decellularised tracheal scaffold seeded with autologous mesenchymal cells and all follow-up procedures.
|
The tracheal graft will be manufactured from cadaveric tracheal scaffold and bone marrow derived mesenchymal cells.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of treatment related SAE's as assessed by CTCAE grades as defined in version 4.0
Time Frame: Up to 8 months post graft
|
Up to 8 months post graft
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy: Post Implant Stent free period
Time Frame: Up to 5 years post implant
|
Up to 5 years post implant
|
|
Efficacy: Post Implant Tracheostomy free period
Time Frame: Up to 5 years post implant
|
Absence of other surgical interventions
|
Up to 5 years post implant
|
Efficacy: Mean Airway Diameter evaluations as captured by CT scans
Time Frame: Up to 5 years post implant
|
Up to 5 years post implant
|
|
Efficacy: Changes in lung function results using a combination of FEV1, FEF50 and PEFR results
Time Frame: Up to 5 years post implant
|
Up to 5 years post implant
|
|
Number of treatment related AEs as assessed by CTCAE grading version 4.0
Time Frame: Upto 5 years post implant
|
Upto 5 years post implant
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Changes in Quality of Life assessed using EQ-5D questionnaires
Time Frame: Up to 5 years post graft.
|
Up to 5 years post graft.
|
Change in Airway Dyspnoea Voice swallowing Index (ADVS)
Time Frame: Up to 5 years post graft.
|
Up to 5 years post graft.
|
Medical Resource Utilisation (MRU) assessed by number and type of tracheal related procedures and treatments post tracheal replacement.
Time Frame: Up to 5 years post graft.
|
Up to 5 years post graft.
|
Change in maximum phonation time (MPT) measured in seconds
Time Frame: Up to and including 5 years post graft
|
Up to and including 5 years post graft
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Martin Birchall, MD, PhD, University College, London
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- D-00173-CT2013002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tracheal Stenosis
-
Asklepios Neurological Clinic Bad SalzhausenRecruiting
-
Johns Hopkins UniversityNot yet recruitingIdiopathic Subglottic Tracheal StenosisUnited States
-
Johns Hopkins UniversityActive, not recruiting
-
Guangzhou Institute of Respiratory DiseaseUnknown
-
Wollo UniversityCompleted
-
University of Modena and Reggio EmiliaCompleted
-
National Research Institute of Tuberculosis and...CompletedTracheal StenosisIran, Islamic Republic of
-
Centre de Recherche de l'Institut Universitaire...RecruitingTracheal StenosisCanada, France
-
Assiut UniversityNot yet recruiting
-
Ludek StehlikUniversity Hospital Olomouc; University Hospital, Motol; Ministry of Health,...Suspended
Clinical Trials on Cadaveric decellularised tracheal scaffold seeded with autologous mesenchymal cells
-
Rumah Sakit Pusat Angkatan Darat Gatot SoebrotoFakultas Kedokteran Universitas Indonesia; RSUPN dr. Cipto Mangunkusumo; Rumah... and other collaboratorsRecruiting
-
Sir Run Run Shaw HospitalCompletedIntrauterine Adhesion | Thin EndometriumChina
-
Affiliated Hospital of Nantong UniversitySecond Affiliated Hospital of Nantong UniversityRecruiting
-
Hospital Infantil Universitario Niño Jesús, Madrid...Instituto de Salud Carlos IIICompletedChildren | Solid Tumors | MetastasesSpain
-
Emdadi Kamyab HospitalNational Taiwan University of Science and TechnologyUnknownNonunion of FractureIran, Islamic Republic of
-
University of BergenHaukeland University Hospital; University of Ulm; Université de NantesCompleted
-
Daniel B. F. SarisRecruitingA Study of REcycled CartiLage Auto/Allo IMplantation to Treat and Repair Focal Hip Cartilage DefectsCartilage DefectUnited States